Abstract
Objective: To evaluate the utility of NESTROFT as a screening test for carriers of thalassemia major.Design: prospective study.Settings and participants: Total 121 clinically normal siblings, of thalassemia major patients who are registered at thalassemia welfare society of J K LON hospital Kota, were selected randomly for study. Intervention: All cases were investigated for CBC, Mentzer’s index, NESTROFT and HbA2 estimation by HPLC method.Result: Total 121 cases were screened for thalassemia carrier by HbA2 estimation using HPLC technique. Out of which total 59 (48.76%) cases showed HbA2 level ≥3.5%considered as carrier while rest 62(51.24%) cases were having normal Hemoglobin pattern. The Sensitivity, specificity, positive predictive value and negative predictive value of MCV<80 are 89.83%, 46.77%, 61.62% and 82.85% respectively.The Sensitivity, specificity, positive predictive value and negative predictive value of Mentzer’s index are 83.05%, 97.36%, 96.07% and 88.09 % respectively.The Sensitivity, specificity, positive predictive value and negative predictive value of NESTROF test are 93.22%, 88.70%, 88.7% and 93.22 % respectively. So NESTROFT is better test (sensitivity is 93.22% and negative predictive value is 93.22%) for screening for Thalassemia carrier.Conclusion - NESTROF test is reliable, cost effective and better screening test for Thalassemia carrier detection. Positive cases can be confirmed by HPLC. NESTROFT can be used in mass hemoglobinopathies screening programmes.
Highlights
In India β-thalassemia is the most common monogenic disorder
In the present study we evaluated the efficacy of one such test, NESTROFT (Naked Eye Single Tube Red Cell Osmotic Fragility Test) in comparison with various other screening parameters in the siblings of thalassemia major patients
Hemoglobinopathies can be suspected on the basis of hematological parameters like reduced mean corpuscular volume (MCV), reduced mean corpuscular hemoglobin (MCH), and elevated RBC count disproportionate to hemoglobin level
Summary
In India β-thalassemia is the most common monogenic disorder. The average incidence of β-thalassemia trait in India is 3.3% with 1-2 per 1,000 couple being at risk of having an affected offspring each year [1]. Manuscript received: 16th May 2016 Reviewed: 26th May 2016 Author Corrected; 12th June 2016 Accepted for Publication: 25th June 2016 to 15% of these children receive optimal treatment [3] The cost of such treatment for one thalassemic child amounts to Rs. 90,000 to 1,00,000 annually at around 3 years of age, which increases as the child, grows [4]. Naked Eye Single Tube Red Cell Osmotic Fragility Test (NESTROFT)- NESTROFT is a rapid, simple and cost effective screening test. In the present study we evaluated the efficacy of one such test, NESTROFT (Naked Eye Single Tube Red Cell Osmotic Fragility Test) in comparison with various other screening parameters in the siblings of thalassemia major patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Pediatric Review: International Journal of Pediatric Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
